Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
Hans-Johachim AndersRichard FurieAna MalvarMing-Hui ZhaoKeiju HiromuraJulia Weinmann-MenkeYulia GreenAngela Jones-LeoneDaniela NegriniRoger A LevyLiz LightstoneYoshiya TanakaBrad H RovinPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
Data suggest consistent benefits of belimumab on kidney outcomes for newly diagnosed and relapsed patients, and irrespective of glucocorticoid pulses at induction.
Keyphrases
- newly diagnosed
- systemic lupus erythematosus
- end stage renal disease
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- clinical trial
- phase iii
- randomized controlled trial
- multiple myeloma
- type diabetes
- machine learning
- adipose tissue
- metabolic syndrome
- weight loss
- insulin resistance
- drug induced